Rethinking the Classification of Pleomorphic Dermal Sarcoma
Pleomorphic dermal sarcoma (PDS) often defies traditional classification systems. While doctors treat it as a soft-tissue sarcoma, new data suggests the tumor is genetically closer to metastatic cutaneous squamous cell carcinoma (CSCC). A retrospective study published in JAMA Dermatology examined tumor sequencing from 49 patients to determine if PDS shares more commonalities with skin carcinomas or traditional sarcomas. Researchers used a 447-gene sequencing assay on tissue samples collected between January 2015 and October 2025. This investigation included nine PDS cases, 15 metastatic CSCC cases, and 25 soft-tissue sarcoma (STS) cases.
The findings highlight a clear divergence from the standard sarcoma grouping. PDS tumors showed a high tumor mutational burden, with a mean of 44.6. This figure sits much closer to the 54.1 mean observed in CSCC than the 4.2 mean found in the STS group. The researchers identified UV signature mutations across all PDS and CSCC samples, a trait completely absent in the soft-tissue sarcoma group. These observations indicate that PDS likely originates from sun-damaged skin rather than the mesenchymal tissues that typically give rise to other sarcomas.
Understanding the Shared Molecular Pathways
Beyond the mutational burden, the study mapped specific genetic pathways affected in these tumor types. Both PDS and CSCC displayed significant mutations in the TP53, cell cycle, NOTCH, and receptor tyrosine kinase–Ras pathways. The soft-tissue sarcoma cohort lacked these specific markers, confirming a distinct molecular difference. This level of genetic overlap suggests that PDS might respond to therapies that work for squamous cell carcinomas, provided the clinical evidence confirms such a shift.
Principal component analysis provided further evidence to support this conclusion. The data points for PDS and metastatic CSCC clustered together, forming a tight group that stood apart from the soft-tissue sarcoma cluster. This visual evidence reinforces the idea that clinical labels often struggle to keep pace with genomic reality. The current classification of PDS as a sarcoma might misguide treatment decisions that could benefit from different pharmacological approaches.
Implications for Clinical Management
This study serves as a critical first step in reevaluating how clinicians approach PDS. Since current management strategies for this tumor remain restricted, identifying a link to CSCC offers a potential path toward more effective care. If future research confirms that PDS shares biological vulnerabilities with squamous cell carcinoma, doctors could begin testing therapies already proven to treat those cancers.
Still, the researchers caution against an immediate shift in practice. The small sample size of nine PDS tumors and the single-center nature of the study limit its current scope. It is not an argument to abandon existing protocols, but rather a call to investigate whether PDS deserves a new place in the oncological diagnostic framework. As the medical field gains better access to gene sequencing, doctors must remain ready to adjust their view of these complex tumors based on specific molecular evidence rather than historical conventions.